Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

Back

ESC Professional Premium Access

Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population

Session: Drug therapy for heart failure: what is new?

Topic: Pharmacotherapy

Speaker: Professor M. Crespo-Leiro (A Coruna, ES)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Professor Maria Generosa Crespo-Leiro

CHUAC, A Coruna (Spain)

42 presentations

3 followers

8 more presentations in this session

Effects of Sacubitril/Valsartan on all-cause hospitalizations in heart failure: participant-level pooled analysis of PARADIGM-HF and PARAGON-HF

Speaker: Doctor H. Lu (Lausanne, CH)

Efficacy of sotagliflozin by diabetes duration: a secondary analysis of SCORED

Speaker: Doctor R. Aggarwal (Boston, US)

Effects of dapagliflozin in heart failure according to duration of type 2 diabetes: a patient-level meta-analysis of DAPA-HF and DELIVER

Speaker: Doctor J. Butt (Copenhagen, DK)

Long-term follow-up of the TRED-HF trial

Speaker: Miss L. Cheng (London, GB)

Utilization and safety of digoxin in patients with chronic heart failure and atrial fibrillation with rapid ventricular rate

Speaker: Doctor K. Berge (Oslo, NO)

Access the full session

Drug therapy for heart failure: what is new?

Speakers: Professor M. Crespo-Leiro, Doctor H. Lu, Doctor R. Aggarwal, Doctor J. Butt, Miss L. Cheng...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources